Mannosylated thiolated paromomycin-loaded PLGA nanoparticles for the oral therapy of visceral leishmaniasis
- PMID: 30688557
- DOI: 10.2217/nnm-2018-0038
Mannosylated thiolated paromomycin-loaded PLGA nanoparticles for the oral therapy of visceral leishmaniasis
Abstract
Aim: The present study evaluates the efficacy of paromomycin (PM)-loaded mannosylated thiomeric nanoparticles for the targeted delivery to pathological organs for the oral therapy of visceral leishmaniasis.
Materials & methods: Mannosylated thiolated chitosan (MTC)-coated PM-loaded PLGA nanoparticles (MTC-PLGA-PM) were synthesized and evaluated for morphology, drug release, permeation enhancing and antileishmanial potential.
Results: MTC-PLGA-PM were spherical in shape with a size of 391.24 ± 6.91 nm and an encapsulation efficiency of 67.16 ± 14%. Ex vivo permeation indicated 12.73-fold higher permeation of PM with MTC-PLGA-PM against the free PM. Flow cytometry indicated enhanced macrophage uptake and parasite killing in Leishmania donovani infected macrophage model. In vitro antileishmanial activity indicated 36-fold lower IC50 for MTC-PLGA-PM as compared with PM. The in vivo studies indicated 3.6-fold reduced parasitic burden in the L. donovani infected BALB/c mice model.
Conclusion: The results encouraged the concept of MTC-PLGA-PM nanoparticles as promising strategy for visceral leishmaniasis.
Keywords: macrophage targeting; mannose receptors; oral therapy; paromomycin; thiolated chitosan; visceral leishmaniasis.
Similar articles
-
Modified solid lipid nanoparticles encapsulated with Amphotericin B and Paromomycin: an effective oral combination against experimental murine visceral leishmaniasis.Sci Rep. 2020 Jul 22;10(1):12243. doi: 10.1038/s41598-020-69276-5. Sci Rep. 2020. PMID: 32699361 Free PMC article.
-
Oral delivery and enhanced efficacy of antimonal drug through macrophage-guided multifunctional nanocargoes against visceral Leishmaniasis.Eur J Pharm Biopharm. 2020 Jul;152:307-317. doi: 10.1016/j.ejpb.2020.05.029. Epub 2020 May 30. Eur J Pharm Biopharm. 2020. PMID: 32485227
-
Development of mannose-anchored thiolated amphotericin B nanocarriers for treatment of visceral leishmaniasis.Nanomedicine (Lond). 2017 Jan;12(2):99-115. doi: 10.2217/nnm-2016-0325. Epub 2016 Nov 23. Nanomedicine (Lond). 2017. PMID: 27879160 Free PMC article.
-
Leishmaniasis: an update of current pharmacotherapy.Expert Opin Pharmacother. 2013 Jan;14(1):53-63. doi: 10.1517/14656566.2013.755515. Epub 2012 Dec 21. Expert Opin Pharmacother. 2013. PMID: 23256501 Review.
-
Macrophage specific drug delivery in experimental leishmaniasis.Curr Mol Med. 2004 Sep;4(6):681-9. doi: 10.2174/1566524043360186. Curr Mol Med. 2004. PMID: 15357216 Review.
Cited by
-
PLGA-Based Nanomedicine: History of Advancement and Development in Clinical Applications of Multiple Diseases.Pharmaceutics. 2022 Dec 6;14(12):2728. doi: 10.3390/pharmaceutics14122728. Pharmaceutics. 2022. PMID: 36559223 Free PMC article. Review.
-
In vitro efficacy of polymer coated miltefosine drug against leishmania tropica.J Parasit Dis. 2022 Jun;46(2):366-376. doi: 10.1007/s12639-021-01452-4. Epub 2021 Sep 23. J Parasit Dis. 2022. PMID: 35692473 Free PMC article.
-
Preclinical Assessment of Ursolic Acid Loaded into Nanostructured Lipid Carriers in Experimental Visceral Leishmaniasis.Pharmaceutics. 2021 Jun 19;13(6):908. doi: 10.3390/pharmaceutics13060908. Pharmaceutics. 2021. PMID: 34205283 Free PMC article.
-
Development and Characterization of PLGA Nanoparticles Containing 17-DMAG, an Hsp90 Inhibitor.Front Chem. 2021 May 13;9:644827. doi: 10.3389/fchem.2021.644827. eCollection 2021. Front Chem. 2021. PMID: 34055735 Free PMC article.
-
Nanotechnology based solutions for anti-leishmanial impediments: a detailed insight.J Nanobiotechnology. 2021 Apr 15;19(1):106. doi: 10.1186/s12951-021-00853-0. J Nanobiotechnology. 2021. PMID: 33858436 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
